Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

25%

1 trials in Phase 3/4

Results Transparency

33%

1 of 3 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 1

2(50.0%)

Phase 2

1(25.0%)

Phase 3

1(25.0%)

4Total

Phase 1(2)

Phase 2(1)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials

NCT07487909Phase 1Completed

A Study of SJP-001 in Comparison With Fexofenadine and Naproxen Administered With Alcohol

Role: lead

NCT05007522Phase 3Completed

Ketotifen and Indomethacin Combination Treatment Clinical Trial for COVID-19

Role: lead

NCT02737397Phase 2Completed

Safety and Efficacy of a Combination Product for the Prevention of Veisalgia

Role: lead

NCT03183297Phase 1Unknown

Study to Evaluate the Pharmacokinetics and Pharmacodynamics of JMI-001

Role: lead

All 4 trials loaded